Cargando…

Aztreonam Lysine Inhalation Solution in Cystic Fibrosis

Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysregulated inflammation. Therapeutic innovations such as nebulized antimicrobial therapy targeting specific pathogens have resulted in improvements in quality of life and life expectancy. Aztreonam lysin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elson, Elizabeth Claire, Mermis, Joel, Polineni, Deepika, Oermann, Christopher M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463232/ https://www.ncbi.nlm.nih.gov/pubmed/31019373 http://dx.doi.org/10.1177/1179548419842822

Ejemplares similares

Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis
por: Daddario, Martha K, et al.
Publicado: (2010)

Role of Inhalational Aztreonam Lysine in Lower Airway Infections in Cystic Fibrosis: An Updated Literature Review
por: Zeb, Mehwish, et al.
Publicado: (2022)

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
por: Heirali, Alya A., et al.
Publicado: (2017)

Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review
por: Kirkby, Stephen, et al.
Publicado: (2011)

Pseudomonas aeruginosa Susceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation
por: Keating, Claire L., et al.
Publicado: (2021)

Lung clearance index to detect the efficacy of Aztreonam lysine inhalation in patients with cystic fibrosis and near normal spirometry – A single-centre feasibility study
por: Ellemunter, Helmut, et al.
Publicado: (2019)

Eradication of Burkholderia cepacia Using Inhaled Aztreonam Lysine in Two Patients with Bronchiectasis
por: Iglesias, A., et al.
Publicado: (2014)

Unraveling the CFTR Function–Phenotype Connection for Precision Treatment in Cystic Fibrosis
por: Zemanick, Edith T., et al.
Publicado: (2019)

235: COVID-19 vaccination in individuals with cystic fibrosis at a pediatric cystic fibrosis center
por: Elson, E., et al.
Publicado: (2021)

High-Frequency Percussive Ventilation in Cystic Fibrosis Patients With Acute Respiratory Failure: A Case Series
por: Jandali, Badr, et al.
Publicado: (2021)

Effects of Levofloxacin, Aztreonam, and Colistin on Enzyme Synthesis by P. aeruginosa Isolated from Cystic Fibrosis Patients
por: Pani, Arianna, et al.
Publicado: (2022)

Optimising inhaled mannitol for cystic fibrosis in an adult population
por: Flume, Patrick A., et al.
Publicado: (2015)

Inhaled therapy in cystic fibrosis: agents, devices and regimens
por: Agent, Penny, et al.
Publicado: (2015)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

Inhaled Biologicals for the Treatment of Cystic Fibrosis
por: Sala, Valentina, et al.
Publicado: (2019)

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
por: Hamed, Kamal, et al.
Publicado: (2017)

Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives
por: Taccetti, Giovanni, et al.
Publicado: (2021)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients
por: Sader, Helio S, et al.
Publicado: (2022)

Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population
por: Polineni, Deepika, et al.
Publicado: (2018)

Aztreonam Lysine Increases the Activity of Phages E79 and phiKZ against Pseudomonas aeruginosa PA01
por: Davis, Carly M., et al.
Publicado: (2021)

Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis
por: Chorepsima, Stamatia, et al.
Publicado: (2018)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria
por: Emeraud, Cécile, et al.
Publicado: (2023)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Nebulizer Care and Inhalation Technique in Children with Cystic Fibrosis
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
por: Nichols, Dave P., et al.
Publicado: (2019)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Prerequisites for a dry powder inhaler for children with cystic fibrosis
por: Lexmond, Anne J., et al.
Publicado: (2017)

Use of inhaled antibiotics among Danish patients with cystic fibrosis
por: Møller, Rikke, et al.
Publicado: (2022)

A pilot study of cystic fibrosis exacerbation response phenotypes reveals contrasting serum and sputum iron trends
por: Gifford, Alex H., et al.
Publicado: (2021)

Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis
por: Terpstra, Lotte C., et al.
Publicado: (2022)

Inhalation with Fucose and Galactose for Treatment of Pseudomonas Aeruginosa in Cystic Fibrosis Patients
por: Hauber, Hans-Peter, et al.
Publicado: (2008)

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis
por: Li, Danni, et al.
Publicado: (2023)

Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report
por: Santos, Roberto P, et al.
Publicado: (2007)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Management of pregnancy in cystic fibrosis
por: Montemayor, Kristina, et al.
Publicado: (2022)

The emergence of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis patients on inhaled antibiotics
por: AbdulWahab, Atqah, et al.
Publicado: (2017)

The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis
por: Dhand, Rajiv
Publicado: (2018)

Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review
por: Martínez-García, Miguel Ángel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ji2agugce0pfu7kso92p9438p